Abstract
BackgroundThe available data on the significance of circulating apelin, chemerin and omentin in women with gestational diabetes mellitus (GDM) are inconsistent. This analysis includes a systematic review of the evidence associating the serum concentrations of these adipokines with GDM.MethodsPublications through December 2019 were retrieved from PubMed, Embase, the Cochrane Library, and Web of Science. Subgroup analysis and meta-regression were conducted to evaluate sources of heterogeneity.ResultsAnalysis of 20 studies, including 1493 GDM patients and 1488 normal pregnant women did not find significant differences in circulating apelin and chemerin levels (apelin standardized mean difference [SMD] = 0.43, 95% confidence interval (CI): − 0.40 to 1.26, P = 0.31; chemerin SMD = 0.77, 95% CI − 0.07 to 1.61, P = 0.07). Circulating omentin was significantly lower in women with GDM than in healthy controls (SMD = − 0.72, 95% CI − 1.26 to − 0.19, P = 0.007). Publication bias was not found; sensitivity analysis confirmed the robustness of the pooled results.ConclusionsCirculating omentin was decreased in GDM patients, but apelin and chemerin levels were not changed. The results suggest that omentin has potential as a novel biomarker for the prediction and early diagnosis of GDM.
Highlights
The available data on the significance of circulating apelin, chemerin and omentin in women with gestational diabetes mellitus (GDM) are inconsistent
GDM was diagnosed based on the American Diabetes Association (ADA) criteria in five studies, the American College of Obstetricians and Gynecologists (ACOG) criteria in three studies, the Carpenter and Couston (C&C) criteria in two studies, the World Health Organization (WHO) criteria in three studies, the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria in four studies, the Australasian Diabetes in Pregnancy Society (ADIPS) criteria in two studies, and National Diabetes Date Group (NDDG) criteria in one study
Overall effects The results showed that there was no significant difference between GDM patients and normal controls in circulating apelin (SMD = 0.43, 95% CI − 0.40 to 1.26, P = 0.31) and chemerin (SMD = 0.77, 95% CI − 0.07 to 1.61, P = 0.07) levels
Summary
The available data on the significance of circulating apelin, chemerin and omentin in women with gestational diabetes mellitus (GDM) are inconsistent. This analysis includes a systematic review of the evidence associating the serum concentrations of these adipokines with GDM. Recent evidence indicates that dysregulation of the secretion of adipokines, which are produced by adipose tissue, is involved in the development of insulin resistance (IR) during pregnancy [8]. A bioactive peptide, was first identified in an extract of bovine stomach tissue.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
